Stromal Vascular Fraction Market

Global Market Study on Stromal Vascular Fraction: Significant Application being Witnessed in Regenerative Medicine

Stromal Vascular Fraction Market Segmented By SVF Isolation Products, Enzymatic Isolation, Non-enzymatic Isolation, Automated POC Devices, SVF Aspirate Purification Products, SVF Transfer Products Therapy in Hospitals, Specialty Clinics, Stem Cell Banks/Laboratories

  • March-2020
  • PMRREP20914
  • 183 Pages
  • Healthcare
  • PPT, PDF, WORD, EXCEL

Introduction

Stromal vascular fraction (SVF) plays a significant role in regenerative medicine and in the treatment of various disorders. Numerous pre-clinical and clinical investigations have been conducted to establish the potential role of stromal vascular fraction for the treatment of osteoarthritis, cartilage regeneration, rheumatoid arthritis, and several soft tissue diseases.

Stromal vascular fraction is a promising tool in orthopaedics, owing to the anti-inflammatory, immune-modulation, and homeostatic properties of SVF, which is anticipated to offer growth opportunities for the stromal vascular fraction market.

Besides, regenerative ability is derived from soluble factors that have multipotent differentiating capabilities, along with heterogeneous cell population containing pericytes, endothelial cells, leukocytes mesenchymal stem cells, and red blood cells. Also, SVF injections are a promising, insignificantly intrusive, non-surgical alternative in the field of orthopedics for the treatment of musculoskeletal disorders.

Find Out More about the Report Coverage

Companies

  • Cytori Therapeutics Inc.
  • IntelliCell BioSciences Inc.
  • Cellular Biomedicines Group, Inc
  • GE Healthcare (Biosafe Group SA)
  • Lifecell Corporation (Allergen PLC)
  • Tissue Genesis Inc
  • InGeneron, Inc.
  • Human med AG
  • MEDICAN CO., LTD

Increasing Clinical Trials for Efficient SVF-derived Cell Therapies

SVF therapies have huge potential in regenerative medicine, and a significant number of clinical trials are being conducted across the globe to evaluate the significance of SVF isolation and processing techniques for different indications.

These clinical trials use proprietary SVF isolation, aspiration, and transfer devices, thus, significantly boosting the growth of the stromal vascular fraction market. Most of these trials are being conducted in the matured market of the U.S. For instance, in 2019, Healeon Medical Inc.

evaluated Centricyte 1000, a closed system digestion of stromal vascular fraction, for use in frailty and aging processes to improve quality of life and functional health. Orthopedic and neurological applications are found to be most attractive in the field of stromal vascular fraction or adipose-derived stem cell therapy.

Customize this Report

Explore Intelligence Tailored to Your Business Goals.

Increasing Demand for Non-enzymatic Isolation of Stromal Vascular Fraction to Benefit Market

Non-enzymatic isolation methods utilize physical forces to separate cells from adipose matrix. Mechanical segregation strategies are alternatives to circumvent safety issues posed by enzymatic protocols.

Non-enzymatic protocols have been endeavored comprising of precisely separating SVF using different devices or an automated closed system, resulting in ready-to-use SVF. To overcome concerns such as high cost, long protocol duration, and regulatory scrutiny, the adoption of non-enzymatic alternatives is increasing for improved volume retention of fat grafts.

In addition, simplification of the technique with improved standardization along with reducing operator-dependent variations makes the non-enzymatic isolation technique more approachable in a clinical practice, and significantly aids the growth of the stromal vascular fraction market.

stromal vascular fraction market

Market Research Methodology - Perfected through Years of Diligence

A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.

Get actionable insights on Ship Repair And Maintenance Services Market

North America to Dominate Stromal Vascular Fraction Market

North America holds a noteworthy share in the stromal vascular fraction market, with 37% of total revenue, and is expected to exhibit a CAGR of around 4% during the forecast period. Growing incidence of skeletal muscular disorders such as osteoarthritis, increasing awareness about stem cell therapy, increasing volume of cosmetic surgeries, and rising demand among clinicians are factors expected to contribute to the dominance of North America in the global stromal vascular fraction market.

Owing to increase in research & development activities in the development of innovative technologies and increasing preference for SVF as an alternative option for better clinical solutions have represented a continuous rise in the demand for advanced technologies, and expansion of private hospitals in rural areas are boosting the demand for stromal vascular fraction in Asia Pacific, which represents the second-most attractive market; it is expected to grow at a CAGR of 4.5% over the forecast period.

Europe is projected to be the third-most lucrative region in the global stromal vascular fraction market, and is expected to exhibit a CAGR of 3.5% during the forecast period.

Explore Persistence Market Research’s expertise in promulgation of the business !

Competitive Landscape of Stromal Vascular Fraction Market

The market is characterized as a fragmented space, with a few key players operating across the globe, such as Cytori Therapeutics Inc., Cellular Biomedicine Group, and others. Investment in R&D to launch new product lines is a key strategy being adopted by manufacturers in the stromal vascular fraction market.

LipoCell from Tissyou, is a promising class IIa medical device that exploits an innovative technology to allow harvesting, which is effective in optimizing fat tissue recuperation for subsequent autologous infusion.

Analysts’ Viewpoint

Technological innovations for new product launches and rising demand for SVF in regeneration medication are responsible for the growth of the stromal vascular fraction market at an impressive rate, with North America and Europe holding substantial share of the global stromal vascular fraction market.

Solid monetary position and new collaboration for the effective management of intravenous infusion are expected to drive the growth of the stromal vascular fraction market over the coming years.

Key Segments of Stromal Vascular Fraction Market

PMR’s study on the stromal vascular fraction market offers information divided into four important segments - product, application, end user, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

Product

  • SVF Aspiration Products
  • SVF Transfer Products
  • SVF Isolation Products
    • Enzymatic Isolation Products
    • Non-enzymatic Isolation Products
    • Automated POC Devices

Application

  • Cosmetic Applications
  • Orthopedic Applications
  • Soft Tissue Applications
  • Others

End User

  • Hospitals
  • Specialty Clinics
  • Stem Cell Banks/Laboratories
  • Others

Region

  • North America
  • Latin America
  • Europe
  • APAC
  • Korea
  • Middle East & Africa

Key Questions Answered in Report

  • How much is the stromal vascular fraction market worth?

    The global stromal vascular fraction market is estimated to reach US$ 76.5 Mn in the year 2021.

  • What will be the demand outlook?

    The global stromal vascular fraction market is expected to grow 1.5 times between 2021 and 2031.

  • What was the last 5 year market CAGR?

    The stromal vascular fraction market witnessed a CAGR of 3.5% between 2015 and 2020.

  • What are the key trends of the stromal vascular fraction market?

    The current trend is that of stromal vascular fraction being increasingly used in the field of orthopaedics due to homeostatic properties, immune-modulation, and anti-inflammatory properties pertaining to stromal vascular fraction.

  • What is driving the demand for stromal vascular fraction?

    The fact that stromal vascular fraction injections happen to be a good non-surgical alternative (as they are negligibly intrusive) is driving the demand for stromal vascular fraction.

  • What is the market share of top 5 players?

    The top 5 players such as Cytori Therapeutica Inc., IntelliCell BioSciences Inc., Cellular Biomedicines Group, Inc., GE Healthcare, and Lifecell Corporation hold more than 50% of the market share.

  • What are the top 5 countries driving demand?

    The top 5 countries driving demand include the US, UK, Russia, India, and China.

  • What is North America’s market Outlook?

    North America holds close to 35% of the overall market revenue.

  • At what percentage stromal vascular fraction market is going to register growth in Europe?

    Europe is expected to register a CAGR of 3% in the stromal vascular fraction market between 2021 and 2031.

  • Which are the key exporters of stromal vascular fraction?

    The US is the major exporter of stromal vascular fraction, followed by UK.

Media Release

Recommendations

Autologous Conditioned Plasma Market

PMR’s market research is based on autologous conditioned plasma therapy market offers information divided into 5 important segments - composition, source, indication, end user & region.

Antiseptic Bathing Market

According to a latest research by the company, the global antiseptic bathing market is anticipated to account for over US$ 549.3 Mn in terms of value, by 2026 end..

Cosmetic Threads Market

Global cosmetic threads market was valued at US$ 114 Mn in 2020, and is expected to witness a CAGR of around 7% during the forecast period (2020 – 2030)..

Scar Treatment Market

Global scar treatment market expects the market to see moderate CAGR growth between 2017-2025 and likely to bring in US$ 13,106 Mn revenue by 2025 end.

Our Clients

Our Clients